KR20240135875A - 개선된 성능 및 안전성을 가진 국소적으로 적용된 항균제의 조성물 및 용도 - Google Patents

개선된 성능 및 안전성을 가진 국소적으로 적용된 항균제의 조성물 및 용도 Download PDF

Info

Publication number
KR20240135875A
KR20240135875A KR1020247029282A KR20247029282A KR20240135875A KR 20240135875 A KR20240135875 A KR 20240135875A KR 1020247029282 A KR1020247029282 A KR 1020247029282A KR 20247029282 A KR20247029282 A KR 20247029282A KR 20240135875 A KR20240135875 A KR 20240135875A
Authority
KR
South Korea
Prior art keywords
synthetic cationic
antimicrobial
cationic polypeptide
polypeptide
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247029282A
Other languages
English (en)
Korean (ko)
Inventor
마이클 피. 베비라쿠아
다니엘 제이. 황
더그 루커
Original Assignee
아미크로베, 인코포레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아미크로베, 인코포레이티드. filed Critical 아미크로베, 인코포레이티드.
Publication of KR20240135875A publication Critical patent/KR20240135875A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
KR1020247029282A 2017-04-06 2018-04-05 개선된 성능 및 안전성을 가진 국소적으로 적용된 항균제의 조성물 및 용도 Ceased KR20240135875A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762482630P 2017-04-06 2017-04-06
US62/482,630 2017-04-06
KR1020197032623A KR20200018400A (ko) 2017-04-06 2018-04-05 개선된 성능 및 안전성을 가진 국소적으로 적용된 항균제의 조성물 및 용도
PCT/US2018/026322 WO2018187617A1 (en) 2017-04-06 2018-04-05 Compositions and uses of locally applied antimicrobials with enhanced performance and safety

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032623A Division KR20200018400A (ko) 2017-04-06 2018-04-05 개선된 성능 및 안전성을 가진 국소적으로 적용된 항균제의 조성물 및 용도

Publications (1)

Publication Number Publication Date
KR20240135875A true KR20240135875A (ko) 2024-09-12

Family

ID=63712780

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247029282A Ceased KR20240135875A (ko) 2017-04-06 2018-04-05 개선된 성능 및 안전성을 가진 국소적으로 적용된 항균제의 조성물 및 용도
KR1020197032623A Ceased KR20200018400A (ko) 2017-04-06 2018-04-05 개선된 성능 및 안전성을 가진 국소적으로 적용된 항균제의 조성물 및 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197032623A Ceased KR20200018400A (ko) 2017-04-06 2018-04-05 개선된 성능 및 안전성을 가진 국소적으로 적용된 항균제의 조성물 및 용도

Country Status (11)

Country Link
US (3) US11285189B2 (https=)
EP (1) EP3606543A4 (https=)
JP (3) JP2020513016A (https=)
KR (2) KR20240135875A (https=)
CN (1) CN110740744A (https=)
AU (2) AU2018249552A1 (https=)
BR (1) BR112019020781A2 (https=)
CA (1) CA3058901C (https=)
MX (2) MX393548B (https=)
SG (1) SG11201909016TA (https=)
WO (1) WO2018187617A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102266659B1 (ko) 2012-03-23 2021-06-17 아미크로베, 인코포레이티드. 조직-적합성 특성을 갖는 항균물질의 조성물 및 용도
CA3058901C (en) 2017-04-06 2025-05-06 Amicrobe, Inc. Compositions and uses of topically applied antimicrobial agents offering improvements in performance and safety
JP2023501385A (ja) * 2019-11-08 2023-01-18 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 抗微生物ペプチドを含む組成物
CN115397454A (zh) * 2020-03-31 2022-11-25 立美基股份有限公司 通过辐照对自组装肽进行灭菌
KR20220166832A (ko) * 2020-04-08 2022-12-19 아미크로베, 인코포레이티드. 바이러스 감염의 예방 및 치료를 위한 국소 적용 합성 아미노산 중합체의 조성물 및 용도
US12371463B2 (en) 2021-04-20 2025-07-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and compositions for treatment of antibiotic-resistant bacterial infections

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5636643A (en) 1991-11-14 1997-06-10 Wake Forest University Wound treatment employing reduced pressure
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6680365B1 (en) 1998-03-19 2004-01-20 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
EP1156781B1 (en) 1999-02-26 2005-06-08 Chiron Corporation Microemulsions with adsorbed macromolecules and microparticles
ES2260291T3 (es) 2000-09-28 2006-11-01 Chiron Corporation Microparticulas para la administracion de acidos nucleicos heterologos.
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
WO2003020797A1 (en) 2001-08-30 2003-03-13 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
JP2003171463A (ja) 2001-12-06 2003-06-20 Chisso Corp ポリリジン及びその製造法
CA2443472A1 (en) 2002-02-07 2003-08-14 Ophtecs Corporation Liquid formulation for contact lenses
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
DE602004012269T2 (de) 2003-07-11 2009-04-30 Theravance, Inc., South San Francisco Quervernetzte glycopeptid-cephalosporin-antibiotika
WO2005018701A1 (en) 2003-08-25 2005-03-03 Kane Biotech Inc. Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
WO2005063278A1 (en) 2003-12-30 2005-07-14 Bioactive Polymers Ab Surface protection of exposed biological tissues
US20080145383A1 (en) 2004-03-12 2008-06-19 Intercell Ag Method for Solubilizing Peptide Mixtures
EP1927597B1 (en) 2004-08-18 2016-11-02 Novabiotics Limited Antibacterial peptides
CA2607841C (en) 2005-06-06 2015-11-24 Novozymes A/S Polypeptides having antimicrobial activity and polynucleotides encoding same
US20080139450A1 (en) 2005-07-01 2008-06-12 Srinivasa Madhyastha Antimicrobial Compositions and Uses Thereof
US20070190110A1 (en) 2006-02-10 2007-08-16 Pameijer Cornelis H Agents and devices for providing blood clotting functions to wounds
CA2671461C (en) 2006-12-01 2014-01-28 The Regents Of The University Of California Vesicles of self-assembling block copolymers and methods for making and using the same
CA2691645A1 (en) 2007-06-25 2008-12-31 Lipopeptide Ab New medical products
EP2192923A2 (en) 2007-08-27 2010-06-09 Massachusetts Institute of Technology Bi-functional polymer-attached inhibitors of influenza virus
CA2727428A1 (en) 2008-06-19 2009-12-23 Nippon Shinyaku Co., Ltd. Drug carrier
CN102256613B (zh) 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
WO2010083589A1 (en) 2009-01-23 2010-07-29 Kane Biotech Inc. Biofilm-removing antimicrobial compositions and uses thereof
GB0905451D0 (en) 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
EA037276B1 (ru) 2010-04-27 2021-03-03 Лисандо Аг Способы устранения или уменьшения бактериальной биопленки
JP5902171B2 (ja) 2010-08-23 2016-04-13 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 高抗微生物活性および低毒性を有する材料の組成物および使用
JP5613779B2 (ja) 2011-01-19 2014-10-29 株式会社メニコン コンタクトレンズ用液剤
US9781949B2 (en) 2011-03-31 2017-10-10 The University Of Massachusetts Antimicrobial delivery systems, methods of manufacture, and methods of use thereof
KR102266659B1 (ko) 2012-03-23 2021-06-17 아미크로베, 인코포레이티드. 조직-적합성 특성을 갖는 항균물질의 조성물 및 용도
DE102014101663A1 (de) 2014-02-11 2015-08-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Synthetische artifizielle Peptide mit antimikrobieller Wirkung
US10351599B2 (en) 2014-09-19 2019-07-16 Tensive Controls, Inc. Anti-microbial peptides
AU2015338969B2 (en) * 2014-10-30 2020-08-27 Biomet Manufacturing, Llc Methods of preventing surgical site infections
JP2016113373A (ja) * 2014-12-11 2016-06-23 エスポ化学株式会社 抗菌性、抗ウイルス性を有する水溶性組成物
CA3058901C (en) 2017-04-06 2025-05-06 Amicrobe, Inc. Compositions and uses of topically applied antimicrobial agents offering improvements in performance and safety
WO2019169324A1 (en) 2018-03-02 2019-09-06 January Therapeutics, Inc. Nanoparticle compositions

Also Published As

Publication number Publication date
US20210100867A1 (en) 2021-04-08
BR112019020781A2 (pt) 2020-04-28
RU2019133628A (ru) 2021-05-06
US20260041728A1 (en) 2026-02-12
CA3058901A1 (en) 2018-10-11
MX393548B (es) 2025-03-24
JP2025090864A (ja) 2025-06-17
CN110740744A (zh) 2020-01-31
EP3606543A4 (en) 2020-12-16
CA3058901C (en) 2025-05-06
JP7656643B2 (ja) 2025-04-03
AU2018249552A1 (en) 2019-10-31
EP3606543A1 (en) 2020-02-12
SG11201909016TA (en) 2019-10-30
US12268722B2 (en) 2025-04-08
RU2019133628A3 (https=) 2021-07-14
MX2022007904A (es) 2022-07-21
JP2023054375A (ja) 2023-04-13
AU2023202283A1 (en) 2023-05-11
US11285189B2 (en) 2022-03-29
WO2018187617A1 (en) 2018-10-11
WO2018187617A8 (en) 2019-10-17
US20230017994A1 (en) 2023-01-19
KR20200018400A (ko) 2020-02-19
JP2020513016A (ja) 2020-04-30

Similar Documents

Publication Publication Date Title
US12268722B2 (en) Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
KR102266659B1 (ko) 조직-적합성 특성을 갖는 항균물질의 조성물 및 용도
JP5203472B2 (ja) キサンタンガムを含む再上皮化医薬組成物
CZ20032771A3 (cs) Farmaceutická kompozice na bázi makrolidů pro lokální podání v očním lékařství
US11173210B2 (en) Temperature-responsive degradable hydrogels
CN109568645B (zh) 一种复合生长因子促修复凝胶及其制备方法与应用
US20230057782A1 (en) Compositions and methods of use thereof for treatment of mastitis
RU2824578C2 (ru) Композиции и применения антимикробных средств для местного применения с улучшенными характеристиками и безопасностью
Mao et al. A review on in situ gels as polymer drug carriers in the treatment of periodontitis
EP3700589A1 (en) Temperature-responsive degradable hydrogels
JP2002511493A (ja) 低溶解度抗生物質による細菌耐性の破壊
EP4356929A1 (en) Antifibrotic formulation for ophthalmic treatment
US20230149333A1 (en) Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections
WO2026060306A1 (en) Compositions and uses of locally applied synthetic cationic and hydrophobic amino acid block copolymers, for prevention and treatment of bacterial and fungal infections
Higaki et al. Corneal collagen shields for ocular drug delivery
JP2023155169A (ja) 眼科用水性組成物
JP2023509400A (ja) 微粒子を含有する医薬組成物の製造方法
MXPA06004865A (en) Suspension of loteprednol etabonate and tobramycin for topical ophthalmic use

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601